Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreements with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
तुलना करने के लिए मीट्रिक्स | NGNE | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधNGNEपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −4.1x | −3.1x | −0.5x | |
PEG अनुपात | 0.00 | 0.00 | 0.00 | |
क़ीमत/बुक | 1.3x | 1.6x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 17.6x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | 165.1% | 77.6% | 50.1% | |
उचित मूल्य अपसाइड | अनलॉक करें | 8.3% | 6.5% | अनलॉक करें |